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The number of available NOACs has provided clinicians with 
a greater range of options for the management of patients 
with thromboembolic disorders. Recently, two meta-analyses 
compared the efficacy and safety of the NOACs in stroke 
prevention in patients with AF [1] and the prevention of 
recurrent venous thromboembolism (VTE) [2]. These meta- 
analyses were the first to include data for all four NOACs 
studied in pivotal phase III studies for these indications.
In the meta-analysis of patients with AF, this included all 
71,683 patients from the RE-LY, ROCKET AF, ARISTOTLE, 
and ENGAGE AF-TIMI 48 studies; in total 42,411 patients 
received a NOAC and 29,272 patients received warfarin. 
Treatment with NOACs was associated with a 19 % decrease 
in the risk of stroke compared with warfarin (relative risk 
0.81, 95 % CI 0.73–0.91; P < 0.0001) (Fig. 4.1).
In patients treated with NOACs, there was a significant 
reduction in all-cause mortality (relative risk 0.90, 95 % CI 
0.85–0.95; P = 0.0003) and intracranial bleeding (relative risk 
0.48, 95 % CI 0.39–0.59; P < 0.0001), however an increase in 
gastrointestinal bleeding was noted (relative risk 1.25, 95 % 
CI 1.01–1.55; P = 0.043). Low-dose NOAC regimens exhibited 
similar rates of stroke and systemic embolic events to warfa-
rin (relative risk 1.03, 95 % CI 0.84–1.27; P = 0.74), with a 
more favorable bleeding profile (relative risk 0.65, 95 % CI 




more ischemic strokes (relative risk 1.28, 95 % CI 1.02–1.60; 
P = 0.045). NOACs were associated with a favorable risk- 
benefit profile compared with warfarin, having demonstrated 
significant reductions in stroke, intracranial hemorrhage and 
mortality and similar rates of major bleeding. The safety and 
efficacy outcomes of NOACs in AF are consistent across a 
wide range of patients.
A similar meta-analysis based on phase III trials compar-
ing NOACs to VKAs in 24,455 patients with VTE was per-
formed, which included five studies, RE-COVER, 
EINSTEIN-DVT, EINSTEIN-PE, AMPLIFY and Hokusai- 
VTE. The risk ratios for VTE, fatal pulmonary embolism and 
overall mortality for NOACs vs VKAs were 0.88 (95 % CI 
0.74–1.05), 1.02 (95 % CI 0.39–5.96), and 0.97 (95 % CI 
0.83–1.14), respectively (Fig. 4.2).
With regards to safety the risk ratio of major bleeding was 
0.60 (95 % CI 0.41–0.88) and fatal bleeding 0.36 (95 % CI 
0.15–0.87). Compared with VKAs, in the treatment of VTE 
NOACs have comparable efficacy with a significantly lower 
risk of bleeding complications.
4.1  Future Directions
The number of NOACs that have been approved or are 
under clinical development reflects the huge clinical demand 
for such medicines and the desire of the pharmaceutical 
industry to respond to the as yet unmet needs of patients.
NOAC (events)    Warfarin (events) RR (95% Cl)
0.5 1.0
Favors NOAC Favors Warfarin
2.0
P
RE-LY 134/6076 199/6022 0.66 (0.53-0.82) 0.0001
ROCKET AF 269/7081 306/7090 0.88 (0.75-1.03) 0.12
ARISTOTLE 212/9120 265/9081 0.80 (0.67-0.95) 0.012
ENGAGE AF-TIMI 48 296/7035 337/7036 0.88 (0.75-1.02) 0.10
Combined (random) 911/29312 1107/29229 0.81 (0.73-0.91) <0.0001
Figure 4.1 Stoke or systemic embolic events. CI confidence inter-
val, NOAC non-VKA oral anticoagulants, RR relative risk 
(Reproduced with permission from Ruff et al. [1])
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Four NOACs, the direct thrombin inhibitor dabigatran 
etexilate and the direct factor Xa inhibitors rivaroxaban, 
apixaban and edoxaban, have already successfully completed 
phase III trials for indications requiring long-term anticoagu-
lation. These drugs largely correspond to the requirements of 
an ideal anticoagulant. Furthermore, as they all participate in 
late stages of the coagulation cascade, their inhibition allows 
disruption of both the intrinsic and the extrinsic pathways; 
their high antithrombotic efficacy stems from this ‘double’ 
action.
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Outcome Study 
Recurrent VTE
Re-Cover (dabigatran) 1.10 0.66 1.84 1.2
Einstein-DVT (rivaroxaban) 0.70 0.46 1.07 16.7
Einstein-PE (rivaroxaban) 1.13 0.76 1.69 18.4
Amplify (apixaban) 0.84 0.60 1.18 25.4
Hokusai (edoxaban) 0.83 0.60 1.14 28.3
Subtotal (I2 = 0%, P = 0.46) 0.88 0.74 1.05 100
Fatal PE
Re-Cover (dabigatran) 0.33 0.03 3.18 18.0
Einstein-DVT (rivaroxaban) 2.98 0.12 73.04 9.0
Einstein-PE (rivaroxaban) 2.00 0.18 21.99 16.0
Amplify (apixaban) 0.50 0.05 5.57 16.0
Hokusai (edoxaban) 1.33 0.30 5.96 41.1
Subtotal (I2 = 0%, P = 0.71) 1.02 0.39 5.96 100
Overall mortality
Re-Cover (dabigatran) 0.99 0.55 1.81 7.1
Einstein-DVT (rivaroxaban) 0.77 0.51 1.17 14.6
Einstein-PE (rivaroxaban) 1.16 0.80 1.68 18.3
Amplify (apixaban) 0.79 0.53 1.19 15.6
Hokusai (edoxaban) 1.05 0.82 1.33 44.4
Subtotal (I2 = 0%, P = 0.50) 0.97 0.83 1.14 100
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Figure 4.2 Efficacy outcomes of non-VKA oral anticoagulants 
(NOACs) vs vitamin K antagonists (VKAs) in phase III prevention 
of venous thromboembolism (VTE) studies. CI confidence interval, 
PE pulmonary embolism, RR relative risk (Reproduced with per-
mission from van der Hulle et al. [2])
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